Jason Auer
Cambridge, Massachusetts, United States
1K followers
500+ connections
About
Highly motivated chemical engineer and technical leader with 15+ years experience…
Activity
-
Excited to share this important work and grateful for all our collaborators as we continue to strive to fulfill the promise of bringing mRNA…
Excited to share this important work and grateful for all our collaborators as we continue to strive to fulfill the promise of bringing mRNA…
Liked by Jason Auer
-
This morning’s building permits and housing starts data were stronger than expected due to a decline in mortgage rates and improved affordability as…
This morning’s building permits and housing starts data were stronger than expected due to a decline in mortgage rates and improved affordability as…
Liked by Jason Auer
-
Moderna and Merck announced today the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating mRNA-4257 (V940), an…
Moderna and Merck announced today the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating mRNA-4257 (V940), an…
Liked by Jason Auer
Experience
-
Nvelop Therapeutics
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
Publications
-
METHODS OF FORMING PARTICLES BY CONTINUOUS DROPLET FORMATION AND DEHYDRATION
United States Patent WO2021212019A1
The present disclosure relates to methods that enable the continuous formation of droplets and dehydration of droplets to provide pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled continuous droplet formation and dehydration that produce circular particles having low internal void spaces comprising bioactive therapeutic biologies.
-
Droplet Formation and Particle Morphology
United States Patent WO2021168271A1
The present disclosure relates to compositions and methods that enable the formation of pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled formation of circular particles having low internal void spaces comprising bioactive therapeutic biologies.
-
Methods of Preparing Lipid Nanoparticles
United States Patent WO2020160397A1
The present disclosure provides novel methods of producing nucleic acid lipid nanoparticle (LNP) formulations, the produced formulations thereof, and the related therapeutic and/or diagnostic uses, such as methods involving the nucleic acid lipid nanoparticles to deliver one or more therapeutics and/or prophylactics, such as a nucleic acid, to and/or produce polypeptides in mammalian cells or organs.
-
Methods of Preparing Lipid Nanoparticles
United States Patent Number US20220062175A1
The present disclosure provides novel methods of producing nucleic acid lipid nanoparticle (LNP) formulations, the produced formulations thereof, and the related therapeutic and/or diagnostic uses, such as methods involving the nucleic acid lipid nanoparticles to deliver one or more therapeutics and/or prophylactics, such as a nucleic acid, to and/or produce polypeptides in mammalian cells or organs.
-
Therapeutic Polymeric Nanoparticle Compositions With High Glass Transition Temperature or High Molecular Weight Copolymers
United States Patent Number US 8,518,963 B2
The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.
Other authors -
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
Science Translational Medicine
We describe the development and clinical translation of a targeted polymeric nanoparticle (TNP) containing the chemotherapeutic docetaxel (DTXL) for the treatment of patients with solid tumors. DTXL-TNP is targeted to prostate-specific membrane antigen, a clinically validated tumor antigen expressed on prostate cancer cells and on the neovasculature of most nonprostate solid tumors. DTXL-TNP was developed from a combinatorial library of more than 100 TNP formulations varying with respect to…
We describe the development and clinical translation of a targeted polymeric nanoparticle (TNP) containing the chemotherapeutic docetaxel (DTXL) for the treatment of patients with solid tumors. DTXL-TNP is targeted to prostate-specific membrane antigen, a clinically validated tumor antigen expressed on prostate cancer cells and on the neovasculature of most nonprostate solid tumors. DTXL-TNP was developed from a combinatorial library of more than 100 TNP formulations varying with respect to particle size, targeting ligand density, surface hydrophilicity, drug loading, and drug release properties. Pharmacokinetic and tissue distribution studies in rats showed that the NPs had a blood circulation half-life of about 20 hours and minimal liver accumulation. In tumor-bearing mice, DTXL-TNP exhibited markedly enhanced tumor accumulation at 12 hours and prolonged
tumor growth suppression compared to a solvent-based DTXL formulation (sb-DTXL). In tumor-bearing mice, rats, and nonhuman primates, DTXL-TNP displayed pharmacokinetic characteristics consistent with prolonged circulation of NPs in the vascular compartment and controlled release of DTXL, with total DTXL plasma concentrations remaining at least 100-fold higher than sb-DTXL for more than 24 hours. Finally, initial clinical data in patients with advanced solid tumors indicated that DTXL-TNP displays a pharmacological profile differentiated from sb-DTXL, including pharmacokinetics characteristics consistent with preclinical data and cases of tumor shrinkage at doses below the sb-DTXL dose typically used in the clinic.Other authors
More activity by Jason
Last week, Oncorus announced a large-scale reduction in force, impacting the full team, myself included. Although we are all deeply saddened by this…
Liked by Jason Auer
My journey with Oncorus has come to an end. I’m grateful for having had the opportunity to work with this amazingly talented team over the past 6…
Liked by Jason Auer
People also viewed
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Jason Auer in United States
-
Jason Auer
-
Jason Auer
-
Jason Auer
Fair Housing Director at Legal Aid of Arkansas
-
Jason Auer
Project Director at Alston Construction
15 others named Jason Auer in United States are on LinkedIn
See others named Jason Auer